Get the Stockscreener App
1.94
8.99%
0.16
Tenax Therapeutics Inc stock is traded at $1.94, with a volume of 4.38M.
It is up +8.99% in the last 24 hours and down -85.96% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$1.78
Open:
$1.815
24h Volume:
4.38M
Relative Volume:
1.21
Market Cap:
$72.60M
Revenue:
-
Net Income/Loss:
$-57.91M
P/E Ratio:
-1.3866
EPS:
-1.3991
Net Cash Flow:
$-38.14M
1W Performance:
-8.92%
1M Performance:
-85.96%
6M Performance:
-83.77%
1Y Performance:
-67.67%
1-Day Range:
$1.80
$1.955
1-Week Range:
$1.7301
$2.11
52-Week Range:
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.94 | 66.61M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Price to book forward of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Enterprise value of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Total revenue of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
RTW Investments, LP Expands Tenax Therapeutics (TENX) Stake Desp - GuruFocus
Tenax Therapeutics (TENX) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Israel Englander funds hold over 5% of Tenax Therapeutics (TENX) - Stock Titan
TENX Q2 2026 Earnings: Narrower Loss Per Share Fails to Offset Stock DeclineEPS Revision Trend - vinanet.vn
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX) - GlobeNewswire
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
Price-Driven Insight from (TENX) for Rule-Based Strategy - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock - Stock Titan
Venrock group (TENX) discloses 1.57M-share warrant-based stake in Tenax - Stock Titan
Perceptive Advisors (TENX) reports beneficial ownership of 1.7M Tenax Therapeutics shares - Stock Titan
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - Kalkine
Tenax Therapeutics (TENX) holder BVF reports 3.11M shares, big warrant overhang - Stock Titan
Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants - Stock Titan
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) - Business Wire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares - Stock Titan
Tenax Therapeutics (TENX) Rallies 6.4% to $1.83, Approaching Key ResistanceNarrow Range Breakout - Vinanet
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics - Morningstar
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) - Morningstar
Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants - Stock Titan
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tenax Therapeutics downgraded to Neutral after ... - Pluang
Tenax Stock Plunges 89% After PH-HFpEF Trial Misses Main Goal, But Subgroup Data Offers Hope - finance.biggo.com
TENX Downgraded by Chardan Capital -- Price Target Lowered to $5 - GuruFocus
CCORF Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Neutral at Chardan Capital - MarketBeat
TENX Maintained by Guggenheim -- Price Target Lowered to $4.00 - GuruFocus
TENX Downgraded by Evercore ISI Group -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Downgraded by Evercore to "In-Line" - MarketBeat
A Quick Look at Today's Ratings for Tenax Therapeutics(TENX.US), With a Forecast Between $4 to $4 - Moomoo
Leerink Partners Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss - Investing.com South Africa
TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - Bitget
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 - marketscreener.com
Tenax Therapeutics’ stock crashes on Phase III trial failure - Yahoo Finance
We're Not Very Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Rate - simplywall.st
TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26 - Bitget
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF PatientsSlideshow (NASDAQ:TENX) 2026-08-11 - Seeking Alpha
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case - MarketBeat
Tenax Therapeutics (TENX) Stock Crashed: Here Is Why - top1markets.com
TENAX THERAPEUTICS INC : CANACCORD GENUITY CUTS TARGET PRICE TO $4 FROM $35 - Bitget
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90% - lincolnjournal.com
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson - GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week LowHere's Why - MarketBeat
William Blair downgrades Tenax Therapeutics stock rating on trial results By Investing.com - Investing.com UK
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 02 '26 |
Buy |
1.80 |
187,704 |
337,586 |
5,624,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 01 '26 |
Buy |
1.80 |
179,058 |
321,570 |
5,436,447 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 21 '26 |
Buy |
1.77 |
716,369 |
1,266,254 |
4,746,444 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 20 '26 |
Buy |
1.78 |
202,124 |
359,538 |
4,030,075 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 24 '26 |
Buy |
1.75 |
107,374 |
188,355 |
4,853,818 |
| Giordano Christopher Thomas | CEO |
Jul 13 '26 |
Option Exercise |
5.88 |
8,719 |
51,267 |
11,324 |
| Rich Stuart | Chief Medical Officer |
Dec 09 '25 |
Buy |
10.22 |
2,500 |
25,542 |
5,266 |
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):